Last 2.43 NOK
Change Today +0.02 / 0.83%
Volume 260.8K
As of 8:24 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

bionor pharma asa (BIONOR) Snapshot

2.44 NOK
Previous Close
2.41 NOK
Day High
2.44 NOK
Day Low
2.40 NOK
52 Week High
03/13/14 - 4.48 NOK
52 Week Low
04/29/14 - 1.91 NOK
Market Cap
Average Volume 10 Days
-0.29 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for BIONOR PHARMA ASA (BIONOR)

Related News

No related news articles were found.

bionor pharma asa (BIONOR) Related Businessweek News

No Related Businessweek News Found

bionor pharma asa (BIONOR) Details

Bionor Pharma ASA, a biotechnology company, is engaged in developing peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). The company’s HIV vaccine candidates in clinical development include Vacc-4x for reducing viral load and killing virus producing cells; and Vacc-C5 is indicated for the formation of antibodies against HIV in humans. The company is also developing Vacc-HIV, a preclinical phase vaccine, using the combination of Vacc-4x and Vacc-C5 vaccines; and Vacc-Flu, a preclinical phase influenza vaccine. In addition, it is developing vaccines for other viral diseases, including Hepatitis C, cytomegalovirus infection, and human papillomavirus infection. Further, the company provides nutraceutical products, such as Nutri5 and NutriPro. It operates in Norway and Europe, including Russia. The company was formerly known as Nutri Pharma ASA and changed its name to Bionor Pharma ASA in June 2010. Bionor Pharma ASA was founded in 1993 and is based in Oslo, Norway.

Founded in 1993

bionor pharma asa (BIONOR) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: 1.3M NOK
Executive Vice President
Total Annual Compensation: 1.9M NOK
Compensation as of Fiscal Year 2013.

bionor pharma asa (BIONOR) Key Developments

Bionor Pharma ASA Reports Earnings Results for the Fourth Quarter of 2014

Bionor Pharma ASA reported earnings results for the fourth quarter of 2014. For the quarter, the company reported EBITDA increased with NOK 10.5 million to negative NOK 12.4 million. Cash Flow from operating activities was negative NOK 10.6 million. Cash at hand at end of fourth quarter of 2014 NOK 93.1 million.

Bionor Pharma ASA, Q4 2014 Earnings Call, Feb 25, 2015

Bionor Pharma ASA, Q4 2014 Earnings Call, Feb 25, 2015

Bionor Pharma ASA to Report Q4, 2014 Results on Feb 25, 2015

Bionor Pharma ASA announced that they will report Q4, 2014 results at 7:00 AM, Central European Standard Time on Feb 25, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIONOR:NO 2.43 NOK +0.02

BIONOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIONOR.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIONOR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 276.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOR PHARMA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at